Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026
SAN FRANCISCO, April 18, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Osteoporosis Therapeutics - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE
What's New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to our digital archives and MarketGlass Research Platform
- Complimentary updates for one year
Edition: 20; Released: February 2022
Executive Pool: 8177
Companies: 53 - Players covered include Alergan Plc.; Amgen, Inc.; Chugai pharmaceutical; Daiichi Sankyo Co., Ltd.; Egalet Corporation; Eisai Co., Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; and Others.
Coverage: All major geographies and key segments
Segments: Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), and Rank Ligand Inhibitors); Route of Administration (Oral, Injectables, and Other Routes of Administration)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry
ABSTRACT-
Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026
Osteoporosis constitutes a bone disorder characterized by a decreased level of bone mineral density (BMD), and/or reduced bone strength, and deterioration of bone architecture, resulting in increased risk of fractures. Afflicting more than 200 million people worldwide, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. The osteoporosis drugs are approved by the FDA for treating Post-Menopausal Osteoporosis (PMO); Osteoporosis in men, and also GIO.
The osteoporosis therapeutics market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up lucrative growth opportunities for pharmaceutical companies. Factors such as aging population, growing awareness of osteoporosis, continuing new product introductions, and expansion of bone densitometry scanning, are expected to steer growth in the market. Amid the COVID-19 crisis, the global market for Osteoporosis Therapeutics estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$14.2 Billion by 2026, registering a compounded annual growth rate (CAGR) of 2.9% over the analysis period. United States represents the largest regional market for Osteoporosis Therapeutics, accounting for an estimated 40.8% share of the global total. The market is projected to reach US$5.5 Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 5.4% over the analysis period.
The US and the Europe are the major markets for Osteoporosis therapeutics. The key factors driving the US and European osteoporosis drugs markets are the existence of well-established healthcare & medical infrastructure, favorable R&D policies towards osteoporosis drug applications, and significant investments in healthcare activities. On the other hand, developing economies are witnessing significant government and private investments in healthcare infrastructure development, driving the market for therapeutic medicines. Healthcare spending in Asia-Pacific is forecast to register a notable expansion fueled by rising consumer income, public healthcare systems' initiatives and lifestyle changes. Despite the availability of a wide variety of treatment options, inadequate awareness of osteoporosis and lack of proper diagnosis equipment have been the major factors plaguing industry growth over the years. More
MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.
Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android
About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.
CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]
LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp
Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./
Follow Us on Twitter
https://twitter.com/marketbytes
Journalists & Media
[email protected]
SOURCE Global Industry Analysts, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=LA26618&Transmission_Id=202204181000PR_NEWS_USPR_____LA26618&DateId=20220418)
Share this article